Ronald S Swerdloff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/518994/publications.pdf

Version: 2024-02-01

97 papers 8,926 citations

43 h-index 49773 87 g-index

102 all docs

102 docs citations

102 times ranked

5802 citing authors

#	Article	IF	CITATIONS
1	Testosterone Replacement Therapy in Hypogonadal Men. Endocrinology and Metabolism Clinics of North America, 2022, 51, 77-98.	1.2	10
2	Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2036-2046.	1.8	4
3	Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e171-e181.	1.8	8
4	What to Measure: Testosterone or Free Testosterone?. , 2021, , 1-13.		0
5	Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11βâ€MNTDC in healthy men. Andrology, 2021, 9, 1526-1539.	1.9	3
6	Relation between Retinopathy and Progression of Coronary Artery Calcium in Individuals with Versus Without Diabetes Mellitus (From the Multi–Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2021, 149, 1-8.	0.7	3
7	Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial. Contraception, 2021, 104, 531-537.	0.8	7
8	Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2142-2149.	1.8	4
9	A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Therapeutic Advances in Urology, 2020, 12, 175628722093723.	0.9	17
	Therapedutor arangee in arcive ₆), 2020, 203		
10	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518.	1.9	8
10		1.9	8 58
	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations		
11	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531. Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical	1.8	58
11 12	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531. Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 66, 83-94. Daily Oral Administration of the Novel Androgen 11î²-MNTDC Markedly Suppresses Serum	1.8	58 7
11 12 13	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531. Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 66, 83-94. Daily Oral Administration of the Novel Androgen 11î²-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e835-e847. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from	1.8	58 7 23
11 12 13	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531. Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 66, 83-94. Daily Oral Administration of the Novel Androgen 11î²-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e835-e847. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246. Combined nestorone–testosterone gel suppresses serum gonadotropins to concentrations	1.8 1.4 1.8	58 7 23 20
11 12 13 14	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2515-2531. Continuing the search for a hormonal male contraceptive. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 66, 83-94. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e835-e847. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246. Combined nestoroneâ€"testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology, 2019, 7, 878-887. Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.	1.8 1.4 1.8 1.9	58 7 23 20 33

#	Article	IF	Citations
19	OR16-1 Best of The Journal of Clinical Endocrinology & Detabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of the Endocrine Society, 2019, 3, .	0.1	O
20	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 681-688.	1.8	79
21	Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E366-E376.	1.8	25
22	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes and Endocrinology, the, 2018, 6, 879-890.	5.5	64
23	Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. Journal of Sexual Medicine, 2018, 15, 997-1009.	0.3	13
24	Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1715-1744.	1.8	1,050
25	Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3083-3093.	1.8	71
26	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	8.9	173
27	Male hormonal contraception: hope and promise. Lancet Diabetes and Endocrinology,the, 2017, 5, 214-223.	5. 5	19
28	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA - Journal of the American Medical Association, 2017, 317, 708.	3.8	289
29	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Internal Medicine, 2017, 177, 471.	2.6	241
30	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	2.6	180
31	Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocrine Reviews, 2017, 38, 220-254.	8.9	123
32	Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary, 2017, 20, 422-429.	1.6	7
33	Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (<scp>DMAU</scp>): a potential oral, male contraceptive. Andrology, 2017, 5, 278-285.	1.9	35
34	Association of endogenous testosterone with subclinical atherosclerosis in men: the multiâ€ethnic study of atherosclerosis. Clinical Endocrinology, 2016, 84, 700-707.	1.2	25
35	Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3096-3104.	1.8	110
36	Emerging medication for the treatment of male hypogonadism. Expert Opinion on Emerging Drugs, 2016, 21, 255-266.	1.0	22

#	Article	IF	CITATIONS
37	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	13.9	675
38	Male Hormonal Contraception: Where Are We Now?. Current Obstetrics and Gynecology Reports, 2016, 5, 38-47.	0.3	49
39	Recruitment and Screening for the Testosterone Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1105-1111.	1.7	28
40	Association of Sex Hormones With Sexual Function, Vitality, and Physical Function of Symptomatic Older Men With Low Testosterone Levels at Baseline in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1146-1155.	1.8	79
41	The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice. Endocrinology, 2015, 156, 4511-4521.	1.4	33
42	Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3280-3287.	1.8	38
43	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	0.7	98
44	A Multicenter, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Klinefelter Syndrome or Anorchia. Journal of Adolescent Health, 2014, 54, 20-25.	1.2	43
45	Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology, 2014, 2, 579-587.	1.9	33
46	Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception, 2014, 90, 407-412.	0.8	59
47	Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage: Clinical, 2014, 4, 454-460.	1.4	107
48	Functional role of progestin and the progesterone receptor in the suppression of spermatogenesis in rodents. Andrology, 2013 , 1 , $308-317$.	1.9	39
49	Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone (sup) \hat{A}^{\otimes} (sup) gels. Andrology, 2013, 1, 899-905.	1.9	27
50	A New Combination of Testosterone and Nestorone Transdermal Gels for Male Hormonal Contraception. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3476-3486.	1.8	85
51	Reexamination of Pharmacokinetics of Oral Testosterone Undecanoate in Hypogonadal Men With a New Selfâ€Emulsifying Formulation. Journal of Andrology, 2012, 33, 190-201.	2.0	43
52	Dietary Fat Modulates the Testosterone Pharmacokinetics of a New Selfâ€Emulsifying Formulation of Oral Testosterone Undecanoate in Hypogonadal Men. Journal of Andrology, 2012, 33, 1282-1290.	2.0	23
53	Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography–tandem mass spectrometry. Steroids, 2011, 76, 177-182.	0.8	196
54	Turnover of nonessential fatty acids in cardiolipin from the rat heart. Journal of Lipid Research, 2011, 52, 2226-2233.	2.0	28

#	Article	IF	CITATIONS
55	Hormonal approaches to male contraception. Current Opinion in Urology, 2010, 20, 520-524.	0.9	51
56	Combined Transdermal Testosterone Gel and the Progestin Nestorone Suppresses Serum Gonadotropins in Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2313-2320.	1.8	65
57	Aging Results in Attenuated Gonadotropin Releasing Hormone-Luteinizing Hormone Axis Responsiveness to Glutamate Receptor Agonist N-Methyl-D-Aspartate*. Journal of Neuroendocrinology, 2008, 10, 93-99.	1.2	67
58	Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids, 2008, 73, 1345-1352.	0.8	73
59	Should hypogonadal men who are suboptimally responsive to testosterone gel switch to another gel preparation?. Nature Reviews Urology, 2008, 5, 190-191.	1.4	1
60	Simultaneous Measurement of Serum Testosterone and Dihydrotestosterone by Liquid Chromatography–Tandem Mass Spectrometry. Clinical Chemistry, 2008, 54, 1855-1863.	1.5	121
61	Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1774-1783.	1.8	106
62	Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet, The, 2006, 367, 1412-1420.	6.3	223
63	Testosterone levels in benign prostatic hyperplasia: sexual function and response to therapy with dutasteride. Nature Reviews Urology, 2006, 3, 528-529.	1.4	0
64	405 MINOCYCLINE THROUGH SUPPRESSION OF CYTOCHROME C AND DIABLO RELEASE ATTENUATES MALE GERM CELL APOPTOSIS AFTER HORMONE WITHDRAWAL. Journal of Investigative Medicine, 2005, 53, S149.3-S149.	0.7	0
65	Advances in male hormone substitution therapy. Expert Opinion on Pharmacotherapy, 2005, 6, 1493-1506.	0.9	23
66	Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2085-2098.	1.8	602
67	A Simple Selfâ€Report Diary for Assessing Psychosexual Function in Hypogonadal Men. Journal of Andrology, 2003, 24, 688-698.	2.0	62
68	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-211.	0.9	52
69	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-211.	0.9	17
70	Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male, 2003, 6, 207-11.	0.9	13
71	Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3562-3572.	1.8	100
72	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients—2002 Update. Endocrine Practice, 2002, 8, 439-456.	1.1	271

#	Article	IF	CITATIONS
73	Neuropsychological profiles of adults with Klinefelter syndrome. Journal of the International Neuropsychological Society, 2001, 7, 446-456.	1.2	114
74	Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clinical Endocrinology, 2001, 54, 739-750.	1,2	151
75	Neurobehavioral phenotype of Klinefelter syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 2000, 6, 107-116.	3.5	176
76	Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 964-969.	1.8	136
77	Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4500-4510.	1.8	287
78	Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2839-2853.	1.8	648
79	Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4500-4510.	1.8	246
80	Suppression of Spermatogenesis in Man Induced by Nal-Glu Gonadotropin Releasing Hormone Antagonist and Testosterone Enanthate (TE) Is Maintained by TE Alone ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3527-3533.	1.8	79
81	Significance of Apoptosis in the Temporal and Stage-Specific Loss of Germ Cells in the Adult Rat after Gonadotropin Deprivation 1. Biology of Reproduction, 1997, 57, 1193-1201.	1.2	140
82	Androgen Replacement Therapy. Annals of Medicine, 1997, 29, 365-370.	1.5	40
83	Androgen deficiency and aging in men. Western Journal of Medicine, 1993, 159, 579-85.	0.3	37
84	Concanavalin A-Immobilized Glycoprotein Antigen for Immunoaffinity Purification of Antiserum. Clinical Chemistry, 1992, 38, 2143-2143.	1.5	0
85	MALE REPRODUCTIVE PHYSIOLOGY. Japanese Journal of Urology, 1990, 81, 1980-1981.	0.0	0
86	Testosterone Doseâ€Dependency of Sexual and Nonsexual Behaviors in The Gonadotropinâ€Releasing Hormone Antagonistâ€Treated Male Rat. Journal of Andrology, 1989, 10, 167-173.	2.0	20
87	Evaluation of the infertile couple. Endocrinology and Metabolism Clinics of North America, 1988, 17, 301-37.	1.2	1
88	<i>In Vitro</i> Inhibition of Testosterone Biosynthesis by Ketoconazole. Endocrinology, 1985, 116, 1920-1925.	1.4	89
89	Lead Toxicity and the Hypothalamic-Pituitary-Testicular Axis. Biology of Reproduction, 1985, 33, 722-728.	1.2	109
90	The Stimulatory and Down-Regulatory Effects of a Gonadotropin-Releasing Hormone Agonist in Man*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 1084-1088.	1.8	40

#	Article	IF	CITATION
91	Nuclear accumulation of estradiol derived from the aromatization of testosterone is inhibited by hypothalamic beta-receptor stimulation in the neonatal female rat Biology of Reproduction, 1984, 30, 388-396.	1.2	43
92	Body Fat at Puberty in Rats: Alteration by Changes in Diet. Pediatric Research, 1979, 13, 7-9.	1.1	33
93	Male Contraception: Clinical Assessment of Chronic Administration of Testosterone Enanthate. Journal of Developmental and Physical Disabilities, 1978, 1, 731-747.	3.6	35
94	Apoptotic Signaling in Male Germ Cells. , 0, , 283-294.		0
95	Temporal and stage-specific changes in spermatogenesis of rat after gonadotropin deprivation by a potent gonadotropin-releasing hormone antagonist treatment. , 0, .		22
96	Spontaneous Expression of Inducible Nitric Oxide Synthase in the Hypothalamus and Other Brain Regions of Aging Rats. , 0, .		35
97	Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone., 0, .		22